This a competitive renewal application for the Cancer Center Support Grant (CCSG) of Roswell Park Cancer Institute (RPCI) for the grant period 2000-2005. This grant is entering its 25th year of uninterrupted funding. Over the last three years RPCI has achieved tremendous new changes in its governance, increased Institutional Commitment to staff recruitment (38 new faculty within the next three years), major renovation of program facilities, expanded philanthropic funding, reorganization of clinical and scientific departments, established interactive scientific and clinical translational programs, strengthened its administrative infrastructure, and enhanced its programmatic relationship with the University at Buffalo. Under the leadership of Dr. David Hohn, President and CEO, RPCI is well-positioned to take advantage of new opportunities and challenges. The Center seeks a significant increase in CCSG funding to match its expanded Institutional commitment. The total request of $3,039,144 will support six scientific programs (Therapeutics, Biophysical Therapies, Immunology, Mouse Molecular Genetics, Cancer Genetics), two disease-oriented programs (Gastrointestinal Oncology, Breast Cancer Research), a Cancer Prevention and Control Program, fourteen shared resources and three clinical support units. The requested support has increased from approximately $1.5 million to $3.0 million. The increase is distributed as follows: New shared resources (25%), increased utilization of existing shared resources. (17%), expansion of shared resources (11%), developmental funds), and requests for salary of senior and program leadership (29%). The funds will be used to support 182 CCSG full members have peer-reviewed funding. With the new leadership, improved environment for basic and translational research, and an increased Institute financial commitment to program development, RPCI is poised to make significant new advances in prevention, early detection, diagnosis and treatment of cancer over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-25
Application #
6089032
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1983-12-01
Project End
2002-04-30
Budget Start
2000-06-28
Budget End
2001-04-30
Support Year
25
Fiscal Year
2000
Total Cost
$1,206,489
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405
Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786
Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527
Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93
Shenoy, Gautam N; Loyall, Jenni; Maguire, Orla et al. (2018) Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 6:236-247

Showing the most recent 10 out of 1555 publications